Research programme: nanoparticle therapeutics - Midatech

Drug Profile

Research programme: nanoparticle therapeutics - Midatech

Alternative Names: Gold nanoparticle encapsulated therapeutics - Midatech; Immuno-oncology TAM MTR- Midatech; Immuno-oncology vaccine MTR - Midatech; MTECHR 01; MTECHT 02; MTECHT 03; MTECHV 02; Nanoparticle bound amoxicillin - Midatech

Latest Information Update: 21 May 2015

Price : $50

At a glance

  • Originator Midatech
  • Developer Dana-Farber Cancer Institute; Midatech
  • Class Cancer vaccines; Viral vaccines
  • Mechanism of Action Cell wall inhibitors; Immunostimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections; Cancer; Viral infections
  • Research Glioblastoma

Most Recent Events

  • 14 Apr 2015 Midatech and Dana-Farber Cancer Institute agree to co-develop nanoparticle therapeutics in United Kingdom and USA for Glioblastoma
  • 14 Apr 2015 Early research in Glioblastoma in United Kingdom (unspecified route)
  • 14 Apr 2015 Early research in Glioblastoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top